We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/10/2017 17:22 | My thoughts FWIW - Good time to add SP currently very weak which is a fantastic opportunity to buy but I have no funds available :( Technically this is now very oversold. Current situation caused ironically by the fact this is a very stickily held stock. Thus causes illiquidity and a couple of chunky sell orders and I guess if theres no commensurate demand for the stock on the order book - down she goes! And thats the problem we have (temporarily I believe) - a lack of demand. Provided theres no bad news lurking in the background - and we've no reason to believe there is because we've only just had a trading update which was positive - then this will bounce back to the mid twenties by the time of the results in December AIMHO DYOR | dibs61 | |
30/10/2017 17:17 | Close to reaching my buying price.... | longshanks | |
27/10/2017 17:09 | Safe trips | longshanks | |
27/10/2017 16:49 | Keep an eye on ODX for me lads, back 23rd November, picked up another 13k first thing as a going away present...LOL....... | barrywhit | |
24/10/2017 13:49 | Hyperboreus, I know you didn't say it had under delivered, and as far as Jam Tomorrow is concerned, It takes years for POC and Diagnostic companies to get their products to market, I should know I was in one for years that eventually got bought out very cheaply. Always set backs and delays expected but they do seem to be at the point of finalizing a few really good products to the market by year end, patience is required for a little bit longer.... | barrywhit | |
24/10/2017 13:37 | barry I didn't actually say that the update had under delivered. I have been a shareholder since early 2012 and to be honest the Company has 'huffed and puffed' during that time, a case of 'jam tommorrow' | hyperboreus | |
24/10/2017 11:51 | Hyperboreus, I wouldn't say that the update under delivered, pretty much in line with what I expected. positive updates on all areas apart from the German Company sales, which then stated the second half would be an improvement... Very happy to hold, as I don't know of another company with such a strong future product line... | barrywhit | |
23/10/2017 19:20 | Easy to say after the event but not too surprised by the share price fall today, one of these fine days Omega might just over deliver, law of averages and all that. Interesting that the results will be announced in the middle of December this year, the only time that they have announced interims results in December before was 10 years ago in 2007 on December 7. Has to be a reason, hope it is something that will be beneficial to all of us on here and not that either the Chairman, Chief Executive or Financial Director are on their jollies until then! 😎 | hyperboreus | |
23/10/2017 10:43 | I too will also be looking to add on further weakness. I can see sellers down to around 20p now - they have a very impatient short term outlook. But we are so close now to a transformational development in this companies history. They remain confident of successful evaluation and CE Mark by end year - that is not long to wait. Investors don’t seem to have twigged that the market they will be entering (re Visitect CD4) is an open door. It’s not like Malaria where there are already a number of competing products. There is a strong need for this POC test and given their links with WHO and UNITAIDS we shouldn’t have long to wait for sales to grow next year. | dibs61 | |
23/10/2017 09:20 | Just a few traders selling out at a loss longshanks in my opinion, investors won't sell on that update too many positives, news by year end expected.... | barrywhit | |
23/10/2017 09:19 | Yes think I will be having some more but as you say lets see how low it will go 20p would be nice or is that just been greedy lol | leedslad001 | |
23/10/2017 09:14 | Worth noting too that the issues with Food Detective appear to have been resolved satisfactorily. Still - there seems little market appetite for the shares right now. A strong hold but I will wait to see how low our current seller wants to take this before buying more. | longshanks | |
23/10/2017 08:24 | The CD4 update is very promising, near term commercialization after field trials evaluation, initial sales of the VISITECT(R) range of Malaria tests manufactured at the facility in Pune, India..CD4 field trials complete, so the factory in Pune is obviously working efficiently.... | barrywhit | |
23/10/2017 08:15 | Agreed. Confident management. Bodes very well for 2018. | verger | |
23/10/2017 08:05 | Always like the way they communicate. Clear, concise, no overly egging the pudding, little to zero repetion. Other companies could learn a few lessons from odx. | p1nkfish | |
23/10/2017 07:59 | Positive update with very promising outlook, moving in the tight direction, more news by year end... | barrywhit | |
23/10/2017 07:55 | Positive update with nothing too much to grab the attention. Visitect CD4 field tests in India are complete though and UK hospital testing due to be completed in the next few weeks. All data and indicators are looking positive so they should have a saleable product by the time they publish interim results. | longshanks | |
23/10/2017 07:13 | Trading update: | hyperboreus | |
22/10/2017 18:29 | IDH trading at an appropriate market value could be a take-out target. Hence, spend the money on buybacks, inflate the price, protect ill performing management. Haven't peeled the onion but the forward multiple looks high given their most recent update. | p1nkfish | |
21/10/2017 17:03 | Surprising thing is the IDH share price has been steadily increasing over the past year from around 180p to 330p. Up almost 80%. Totally at odds with the lacklustre performance and statements from the company within the same period. Perhaps it’s due to the share buyback as they have a large amount of cash they’re doing nothing with otherwise. | dibs61 | |
20/10/2017 20:01 | No wonder IDH are in the middle of a share buyback, no one else would buy their shares..... | barrywhit | |
20/10/2017 19:54 | What a trading update and after hours quite disgusting from IDH. the only product keeping them afloat is their iSYS system, sounds like they really need ODX for any future growth, they are lucky they have a healthy bank balance... | barrywhit | |
20/10/2017 19:18 | Quick look at the IDH trading update and no wonder they released after hours Friday. ODX needs winners as partners. | p1nkfish | |
20/10/2017 18:42 | Time we ditched idh and found a new platform must be more than this company out there | leedslad001 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions